Table 3.
Associations between serum holotranscobalamin (holoTC) and metabolic risk factors; Cameroon study.
| Outcome | Difference in Outcome per 1 SD (34.3 pmol/L) of Serum holoTC | |||||
|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | ||||
| β (95% CI) | p-Value | β (95% CI) | p-Value | β (95% CI) | p-Value | |
| Metabolic syndrome score, (n = 491) | 0.33 (0.10 to 0.56) | 0.004 | 0.17 (−0.05 to 0.39) | 0.127 | 0.04 (−0.16 to 0.23) | 0.70 |
| Systolic blood pressure (mmHg), (n = 500) | 1.72 (0.001 to 3.44) | 0.050 | 0.49 (−1.16 to 2.14) | 0.561 | 0.08 (−1.60 to 1.76) | 0.923 |
| Diastolic blood pressure (mmHg), (n = 500) | 1.50 (0.39 to 2.62) | 0.008 | 0.65 (−0.42 to 1.71) | 0.234 | 0.32 (−0.75 to 1.38) | 0.561 |
| Fasting blood glucose (mmol/L), (n = 500) | 0.10 (−0.03 to 0.22) | 0.121 | 0.07 (−0.07 to 0.21) | 0.323 | 0.05 (−0.09 to 0.18) | 0.502 |
| 2-h blood glucose (mmol/L), (n = 494) | 0.22 (0.05 to 0.40) | 0.014 | 0.12 (−0.05 to 0.30) | 0.162 | 0.12 (−0.06 to 0.29) | 0.187 |
| HOMA-IR, (n = 497) | 0.09 (−0.003 to 0.18) | 0.059 | 0.12 (0.03 to 0.23) | 0.012 | 0.08 (−0.01 to 0.18) | 0.075 |
| Triglycerides (mmol/L), (n = 491) | 0.03 (−0.006 to 0.07) | 0.10 | 0.02 (−0.02 to 0.06) | 0.313 | 0.01 (−0.03 to 0.05) | 0.475 |
| HDL cholesterol (mmol/L), (n = 491) | 0.02 (−0.01 to 0.05) | 0.165 | 0.01 (−0.02 to 0.03) | 0.678 | 0.01 (−0.02 to 0.04) | 0.647 |
HOMA-IR, homeostatic model assessment of insulin resistance; β, β-coefficient; CI, confidence interval. Model 1: Unadjusted. Model 2: Adjusted for age, sex, education level, smoking, alcohol intake, residential site. Model 3: Model 2 + body mass index + objectively measured physical activity.